CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES
Background. NXT007, a next-generation bispecific antibody based on emicizumab that mimics activated factor (F)VIII function in people with hemophilia A (HA), was investigated in two Phase I/II, open-label, non-randomized, multicenter, multiple-ascending-dose (MAD) studies: one in Asia (NXTAGE Part B; jRCT2080224835) an...